Health Care [ 12/12 ] | Biotechnology [ 62/74 ]
NASDAQ | Common Stock
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients.
Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.
The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy.
In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs.
Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 12, 24 | -0.37 Increased by +7.53% | - |
| Aug 13, 24 | -0.40 Decreased by -53.85% | -0.39 Decreased by -2.56% |
| May 13, 24 | -0.38 Increased by +28.30% | -0.42 Increased by +9.52% |
| Mar 28, 24 | -0.38 Increased by +15.56% | -0.48 Increased by +20.83% |
| Nov 13, 23 | -0.40 Increased by +29.82% | -0.52 Increased by +23.08% |
| Aug 14, 23 | -0.26 Increased by +62.32% | -0.49 Increased by +46.94% |
| May 12, 23 | -0.53 Increased by +11.67% | -0.41 Decreased by -29.27% |
| Mar 30, 23 | -0.45 Increased by +33.82% | -0.48 Increased by +6.25% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | N/A Decreased by N/A% | -43.87 M Decreased by -13.50% | - - |
| Jun 30, 24 | 0.00 Decreased by N/A% | -43.87 M Decreased by -76.26% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -38.02 M Increased by +25.02% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 6.91 M Increased by +N/A% | -37.16 M Increased by +13.93% | Decreased by -537.53% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -38.65 M Increased by +28.26% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -24.89 M Increased by +61.51% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -50.71 M Increased by +6.94% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -43.17 M Increased by +28.96% | Decreased by N/A% Decreased by N/A% |